ADC Therapeutics
ADCT
53 hedge funds and large institutions have $891M invested in ADC Therapeutics in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 19 reducing their positions, and 10 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
9% more capital invested
Capital invested by funds: $816M → $891M (+$74.4M)
0.97% less ownership
Funds ownership: 43.7% → 42.74% (-0.97%)
5% less funds holding
Funds holding: 56 → 53 (-3)
18% less call options, than puts
Call options by funds: $1.11M | Put options by funds: $1.35M
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
32% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.26M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$3.24M |
| 3 |
JP Morgan Chase
New York
|
+$1.79M |
| 4 |
ERSOT
Employees Retirement System of Texas
Austin,
Texas
|
+$922K |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$708K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$34.5M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$10.2M |
| 3 |
Morgan Stanley
New York
|
-$4.22M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$1.22M |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$1.03M |
ADCT Hedge Fund Activity: Q3 2021 in Review
53 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q3 2021, worth a combined $891M — up 9.1% from $816M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ADCT and 7 opened new positions — a net loss of 3 holders — while 19 trimmed existing stakes and 13 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $4.26M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $34.5M sold.
- 53 institutional investors held ADC Therapeutics (ADCT) as of Q3 2021, down from 56 in Q2 2021.
- Funds reported $891M of ADC Therapeutics stock for Q3 2021, up 9.1% quarter-over-quarter.
- 7 funds opened new ADC Therapeutics positions in Q3 2021 and 10 closed out, a net change of -3 holders.
- The largest ADC Therapeutics buyer in Q3 2021 was T. Rowe Price Associates, an estimated $4.26M added.
- The largest ADC Therapeutics seller in Q3 2021 was Baker Bros. Advisors, an estimated $34.5M sold.
Based on aggregated 13F filings for Q3 2021.